<div id="readability-page-1"><div> <p>Health-care companies rose amid optimism about obesity-drug demand.</p> <p>   Shares of Novo Nordisk rose after the U.S. Food and Drug Administration approved the first GLP-1 weight-loss pill, a tablet formulation of the Danish company's drug branded as both Ozempic and Wegovy. The availability of pills for the medications that had already seen high demand in injection form is anticipated to bolster demand for the glucagon-like peptide inhibitors. </p> <p>   Shares of some other obesity-drug makers, including Viking Therapeutics, rose in sympathy. </p> <p>   A Baltimore city jury ordered Johnson &amp; Johnson to pay over $1.5 billion in a lawsuit that alleged the company's talc-based personal products gave a Maryland woman cancer. </p> <pre></pre> <p>   Write to Rob Curran at rob.curran@dowjones.com </p> <p>   (END) Dow Jones Newswires</p> <p>   December 23, 2025 18:13 ET (23:13 GMT)</p><p>Copyright (c) 2025 Dow Jones &amp; Company, Inc.</p></div></div>

諾和諾德公司

Viking治療

<p>醫療保健股票因對肥胖藥物需求的樂觀情緒而上漲，諾和諾德公司的股票在其 GLP-1 減肥藥獲得 FDA 批准後上漲。預計該藥物將增加對類胰高血糖素肽抑制劑的需求。其他肥胖藥物製造商的股票，如 Viking Therapeutics，也有所上漲。此外，強生公司被判支付超過 15 億美元的賠償金，因其滑石粉產品被指控導致癌症</p>

醫療保健板塊上漲，諾和諾德公司股價上升——醫療保健綜述